Stay updated with breaking news from Prof Dave Singh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory approval for first patient study of first non-antibiotic macrolideREYKJAVIK, Iceland, November 14, 2022 / B3C newswire / -- EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to...
Regulatory approval for first patient study of first non-antibiotic macrolide EpiEndo Pharmaceuticals ('EpiEndo'), the clinical-stage biopharmaceutical company developing therapeutics for chronic
First non-antibiotic macrolide to go into clinical development targeting COPD Safety, tolerability and pharmacokinetic endpoints met Phase II planning underway EpiEndo Pharmaceuticals
First non-antibiotic macrolide to go into clinical development – targeting COPDSafety, tolerability and pharmacokinetic endpoints metPhase II planning underwayREYKJAVIK, Iceland, May 18, 2022 / B3C newswire / -- EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modi...